Lovenox enoxaparin: Phase II; marketed

Researchers presented data from the 483-patient Phase II ENTIRE-TIMI 23 trial that showed similar TIMI 3 flow rates (a measure of coronary blood flow) after 60 minutes, the primary end point, in patie...